Wahed FTSE USA Shariah ETF vs Medtronic PLC — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.95, while Medtronic PLC trades at $90.72 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| HLAL | MDT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $105.35 |
52-Week Low | $55.52 | $73.75 |
Market Cap | — | $116.07B |
Enterprise Value | — | $134.82B |
Dividend Yield | — | 3.18% |
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $73.11 with a slight 0.19% daily gain, showing bullish technical momentum with strong moving average support. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data, and a small dividend of $0.02 is scheduled for June 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautiously optimistic given bullish technical trends, but limited fundamental data and high RSI levels near 95 warrant monitoring. Key risks include reliance on technical momentum without clear valuation anchors, while institutional sentiment appears constructive based on moving average alignment.
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →